

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

Recombinant Anti-FOXM1 antibody [EPR17379]

RRID:AB_3068347

Type: Antibody

Proper Citation

Abcam Cat# ab207298, RRID:AB_3068347

Antibody Information

URL: http://antibodyregistry.org/AB_3068347

Proper Citation: Abcam Cat# ab207298, RRID:AB_3068347

Target Antigen: FOXM1

Host Organism: Rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IHC-P, ICC/IF

Antibody Name: Recombinant Anti-FOXM1 antibody [EPR17379]

Description: This recombinant monoclonal targets FOXM1

Target Organism: mouse, human

Clone ID: EPR17379

Antibody ID: AB_3068347

Vendor: Abcam

Catalog Number: ab207298

Record Creation Time: 20231110T031031+0000

Record Last Update: 20260831T231344+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-FOXM1 antibody [EPR17379].

No alerts have been found for Recombinant Anti-FOXM1 antibody [EPR17379].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gao Y, et al. (2026) Reprogramming tumour-associated macrophages in breast cancer via si-FOXM1-loaded lipid nanoparticles enhances immune checkpoint inhibitor efficacy. British journal of pharmacology, 183(11), 3049.

Noorizadeh R, et al. (2025) YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1-mediated reprogramming of bone mesenchymal stem cells. Cell reports, 44(3), 115381.

Li Q, et al. (2024) DDX56 promotes EMT and cancer stemness via MELK-FOXM1 axis in hepatocellular carcinoma. iScience, 27(6), 109827.

Liu K, et al. (2024) Ubiquitin-specific peptidase 22 controls integrin-dependent cancer cell stemness and metastasis. iScience, 27(9), 110592.